Will the FDA approve CagriSema for weight management before 31 December 2026?
deadline 2026-12-31
confidence medium
tier 2 evidence
37%PolySignal estimate
Resolution criterion
Yes if the FDA approves the NDA by 31 December 2026 (Drugs@FDA or a Novo Nordisk release). A complete response letter, a postponement of the PDUFA date, or the absence of a decision by that date count as no.
Verified starting state
NDA filed on 18 December 2025 for weight management, with Novo indicating an FDA review "in 2026". Caution: no official PDUFA date was found in a primary source; industry trackers place the decision in the fourth quarter of 2026. REDEFINE-1 had missed the internal target of 25% weight loss.
What pushes it up
- Positive efficacy data showing greater weight loss than Lilly rival (Reuters) [tier 2]
- Reports of superior weight loss in late‑stage diabetes trial (Pharmaceutical Executive) [tier 3]
What pushes it down
- Novo reports “couple of setbacks” in R&D and mixed data (Fierce Biotech) [tier 2]
- Submaximal dose results suggest less than expected efficacy (Pharmaceutical Technology) [tier 3]
What would move this number most
The official PDUFA date or any FDA communication confirming the review timeline would most shift the estimate.
How this number is built
| Deadline | 2026-12-31 |
| Base rate | 28% |
| Best evidence | tier 2 · 5 article(s) used |
| Independent runs | 36 · 38 (spread 2 pts) |
| Confidence | medium |
| Evidence cap | not triggered |
| Last revised | 2026-10-02 09:08 |
| Model | openai/gpt-oss-120b (Groq) |
Sources consulted
Probability history
2026-10-02 09:08 37% 34 article(s) on file · openai/gpt-oss-120b (Groq)
- What pushes it up. Positive efficacy data showing greater weight loss than Lilly rival (Reuters) [tier 2]
- What pushes it up. Reports of superior weight loss in late‑stage diabetes trial (Pharmaceutical Executive) [tier 3]
- What pushes it down. Novo reports “couple of setbacks” in R&D and mixed data (Fierce Biotech) [tier 2]
- What pushes it down. Submaximal dose results suggest less than expected efficacy (Pharmaceutical Technology) [tier 3]
- What would move this number most. The official PDUFA date or any FDA communication confirming the review timeline would most shift the estimate.
2026-09-30 17:02 45% 27 article(s) on file · openai/gpt-oss-20b (Groq)
- What pushes it up. Positive trial data and strong Novo track record, as reported by Reuters [tier 2] and Pharmaceutical Executive [tier 3]
- What pushes it up. NDA filed and review scheduled for 2026, indicating FDA intent to evaluate the product [tier 1]
- What pushes it down. Mixed data and missed weight‑loss target in REDEFINE‑1, reported by Pharmaceutical Technology [tier 3]
- What pushes it down. Safety signals in FAERS and industry concerns about potential regulatory delays, highlighted by Fierce Biotech and Investir Les Echos [tier 2]
- What would move this number most. Whether the FDA will issue a complete response letter or postpone the PDUFA date, which would delay or prevent approval by 31 Dec 2026.
2026-09-28 09:09 34% 2 article(s) on file · openai/gpt-oss-20b (Groq)
- What pushes it up. Industry trackers place the decision in Q4 2026, suggesting a higher likelihood of approval by the deadline. [tier 4]
- What pushes it up. The NDA was filed on 18 Dec 2025 with a review scheduled in 2026, indicating the drug is in the first review cycle. [tier 4]
- What pushes it down. No official PDUFA date has been released, and the FDA has not yet issued a decision. [tier 4]
- What pushes it down. The lack of tier 1 or tier 2 confirmation means the information is weak and could be inaccurate. [tier 4]
- What would move this number most. The official PDUFA date and the actual FDA decision by 31 Dec 2026.
2026-09-27 09:02 37% 2 article(s) on file · gemini-3.6-flash
- What pushes it up. The NDA was submitted on 18 December 2025 and accepted for review, keeping an official decision window within Q4 2026 [tier 1]
- What pushes it up. CagriSema builds on semaglutide, an already FDA-approved moiety with an established safety profile [tier 1]
- What pushes it down. REDEFINE-1 missed its internal target of 25% weight loss, which could complicate label discussions or clinical evaluation [tier 1]
- What pushes it down. Any PDUFA extension or Complete Response Letter (CRL) before 31 December 2026 automatically results in a NO outcome [tier 1]
- What would move this number most. Whether the FDA issues a decision within the standard 10-month review window without requiring additional data or extending the PDUFA date into 2027.
2026-09-21 22:27 36% 0 article(s) on file · openai/gpt-oss-120b (Groq)
Reasons not recorded for this revision (detailed history has only been kept since recently).
2026-09-19 07:38 68% 0 article(s) on file · gemini-3.6-flash
Reasons not recorded for this revision (detailed history has only been kept since recently).